



Lentigen™

NEWS RELEASE

Lentigen Appoints Tim Ravenscroft as Chief Executive Officer

Baltimore, MD, (January 28, 2008) - Lentigen Corporation today announced the appointment of Tim Ravenscroft as chief executive officer.

David Wetherell, Lentigen's chairman, commented, "The board of Lentigen is delighted that Tim has agreed to lead Lentigen, as we are about to enter clinical trials for our first therapies later this year for Glioblastoma and GVHD. His particularly strong background and global leadership in healthcare products will serve Lentigen well as we advance with our broad set of product lines, therapeutics and collaborations."

Having most recently served as president of Bristol-Myers Squibb (BMS) Medical Imaging, Mr. Ravenscroft has more than 29 years' international experience in healthcare product development and commercial management. He has also held executive and senior positions with BMS' Global Virology Franchise, Dupont Pharmaceutical's Global HIV Business, and Glaxo Wellcome.

"Tim's strong background in HIV at BMS, DuPont and Glaxo Wellcome further bolsters Lentigen as we consider our own initiatives and collaborations in this arena," said Mr. Wetherell. "Certainly, the world needs superior solutions to address this disease, and with Tim's presence, Lentigen is better positioned than ever to play a key role."

Mr. Ravenscroft said, "Lentigen is poised to take a leading role in areas of biomedicine where Lentiviral vectors can play a decisive role. The company has a clear commitment to the improvement of health outcomes for patients in several disease areas and I am greatly looking forward to leading the corporation through its further growth and development."

Lentigen's founder Dr. Boro Dropulic, who will retain the roles of president and chief scientific officer, commented, "I am delighted that Tim has joined Lentigen and I look forward to an effective partnership that will take Lentigen to the next level."

Mr. Ravenscroft holds a bachelor's degree in applied biology from North East London University and a master's degree in information sciences from City University in the United Kingdom.

About Lentigen Corporation

Lentigen Corporation is a privately owned biotechnology company focused on the development of lentiviral vector technology for a wide range of therapeutic, vaccine, and research applications in biotechnology and medicine. Lentiviral vectors are the most efficient vehicles for the delivery of genes or gene silencing sequences stably into cells. Lentigen is a highly collaborative company, co-developing Lentiviral vector-based products across a broad spectrum of bench to clinical applications. Partnerships include The National Institutes of Health, The University of Pennsylvania, ThermoFisher Scientific and The U.S. Army. For further information, visit www.lentigen.com <<http://www.lentigen.com>>. Contact:

Gregory Tiberend

gtiberend@rlcinc.com

Meghan Feeks

mfeeks@rlcinc.com

Richard Lewis Communications, Inc.

212-827-0020